IP Library › Granted Patent US 9,687,571
Granted Patent B2
US 9,687,571 · App. 13/264,276 · Granted Jun 27, 2017

Stabilization of radiopharmaceutical compositions using ascorbic acid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,687,571
App. No.
13/264,276
Granted
Jun 27, 2017
Kind
B2
Abstract

Radiopharmaceutical compositions, and related methods, useful for medical imaging are provided. The radiopharmaceutical compositions include one or more radiopharmaceutical compounds, together with a stabilizer comprising ascorbic acid, wherein the pH of said composition is within the range of about 3.5-5.5.

Claims (23)

1. A composition, comprising a radiopharmaceutical compound of formula:

and ascorbic acid,

wherein the pH of said composition is within a range of about 3.5 to less than 6; and

wherein the composition comprises between about 25 mg/mL and 500 mg/mL of ascorbic acid.

2. The composition of claim 1 wherein the composition comprises greater than about 50 mg/mL of ascorbic acid.

3. A method for preparing a radiopharmaceutical composition of claim 1 , comprising:

contacting a first solution comprising a radiopharmaceutical compound of formula:

with a second solution comprising ascorbic acid within a pH range of about 3.5 to less than 6, to form the radiopharmaceutical composition comprising the radiopharmaceutical compound and ascorbic acid,

wherein the composition comprises between about 25 mg/mL and 500 mg/mL of ascorbic acid.

4. A method of myocardial imaging a patient, comprising:

administering to the patient a radiopharmaceutical composition comprising a radiopharmaceutical compound of formula:

and ascorbic acid,

wherein the pH of the composition is within a range of about 3.5 to less than 6, and

wherein the composition comprises between about 25 mg/mL and 500 mg/mL of ascorbic acid; and

obtaining a myocardial image of the patient.

5. The composition of claim 1 , wherein the composition comprises between about 25 mg/mL and 200 mg/mL of ascorbic acid.

6. The composition of claim 1 , wherein the composition comprises greater than about 40 mg/mL of ascorbic acid.

7. The composition of claim 1 , wherein the composition comprises between about 50 mg/mL and 200 mg/mL of ascorbic acid.

8. The composition of claim 1 , wherein the composition comprises about 50 mg/mL of ascorbic acid.

9. The composition of claim 1 , wherein said pH is within the range of about 5.5 to less than 6.

10. The composition of claim 9 , wherein the pH is 5.8.

11. The composition of claim 5 , wherein said pH is within the range of about 5.5 to less than 6.

12. The composition of claim 11 , wherein the pH is 5.8.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Jun 27, 2019
From: JPMORGAN CHASE BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 049623/0123 →
NOTICE OF SUCCESSION OF AGENCY Recorded May 25, 2017
From: CREDIT SUISSE AG
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 042586/0699 →
RELEASE OF SECURITY INTEREST IN CERTAIN PATENTS Recorded May 25, 2017
From: JPMORGAN CHASE BANK, N.A.
To: LANTHEUS MEDICAL IMAGING, INC.
Reel/Frame 042586/0710 →
RELEASE OF SECURITY INTEREST IN CERTAIN PATENTS Recorded Mar 30, 2017
From: WELLS FARGO BANK, NATIONAL ASSOCIATION
To: LANTHEUS HOLDINGS, INC.; LANTHEUS MEDICAL IMAGING, INC.; LANTHEUS MI REAL ESTATE, LLC
Reel/Frame 042115/0715 →
SECURITY AGREEMENT Recorded Jun 30, 2015
From: LANTHEUS MEDICAL IMAGING, INC.
To: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, AS COLLATERAL AGENT
Reel/Frame 036013/0516 →
AMENDMENT NUMBER ONE TO GRANT OF A SECURITY INTEREST - PATENTS Recorded Jul 3, 2013
From: LANTHEUS MI INTERMEDIATE, INC.; LANTHEUS MEDICAL IMAGING, INC.; LANTHEUS MI REAL ESTATE, LLC
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 030747/0814 →